WebNews
Please enter a web search for web results.
NewsWeb
How Electronic Patient-Reported Outcomes Are Transforming Symptom Management and Value-Based Cancer Care
5+ hour, 29+ min ago (992+ words) In this interview, Deborah Patt, MD, Ph D, MBA, discusses data presented at the 2026 American Society of Clinical Oncology Annual Meeting showing how electronic patient-reported outcomes and remote therapeutic monitoring can improve symptom management, reduce hospitalizations and total cost of…...
Isatuximab Retreatment After Prior Anti-CD38 Therapy in Relapsed or Refractory Multiple Myeloma
6+ hour, 29+ min ago (444+ words) HMP Global Learning Network Insights from the ASCO Annual Meeting Isatuximab Retreatment After Prior Anti-CD38 Therapy in Relapsed or Refractory Multiple Myeloma - Design/Population: Post hoc analysis of the phase 3 IRAKLIA trial evaluating isatuximab plus pomalidomide and dexamethasone in 67 patients…...
Sacituzumab Govitecan Plus Pembrolizumab Delivers Benefit Independent of TROP2 Expression in Triple-Negative Breast Cancer
6+ hour, 29+ min ago (236+ words) Results demonstrated consistent benefit with sacituzumab govitecan plus pembrolizumab across all biomarker-defined subgroups, including patients with low TROP2 expression, BRCA wild-type disease, and HER2 IHC 0 tumors. These findings reinforce the broad activity of the regimen and support its use as a frontline…...
Prosigna-Guided Treatment Safely Reduces Chemotherapy Use in HR-Positive, HER2-Negative Early Breast Cancer
6+ hour, 29+ min ago (241+ words) Dr Stein presented these results at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois." Hello, I'm Rob Stein, I'm a professor of medical oncology at University College London in England. I'm talking about the OPTIMA trial....
PR21 PLUTO Supports Flexible Sequencing of Docetaxel and Lutetium-177 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
8+ hour, 7+ min ago (211+ words) Dr Chi presented these results at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois." Hi, I'm Dr Kim Chi, a medical oncologist at BC Cancer Vancouver Centre. I'm also affiliated with the Vancouver Prostate Centre and…...
Neoadjuvant Nivolumab Plus Relatlimab Produces Deep Responses in High-Risk Melanoma
6+ hour, 44+ min ago (279+ words) Dr Long presented these results at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois." Between October 2023 and October 2025, we enrolled 20 patients: 8 with stage IIA disease, 8 with stage IIB disease, and 4 with stage IIC disease. All patients…...
Adding Tafasitamab and Lenalidomide to R-CHOP Improves Outcomes in High-Risk Diffuse Large B-Cell Lymphoma
6+ hour, 34+ min ago (338+ words) John Burke, MD, Rocky Mountain Cancer Centers, Denver, Colorado, discusses results from the phase 3 front MIND trial evaluating tafasitamab plus lenalidomide in combination with R-CHOP for previously untreated high-risk diffuse large B-cell lymphoma. The study enrolled a particularly high-risk patient…...
TLX591 Shows Prolonged Tumor Retention With Limited Off-Target Radiation Exposure in Metastatic Castration-Resistant Prostate Cancer
8+ hour, 23+ min ago (608+ words) HMP Global Learning Network Insights from the ASCO Annual Meeting TLX591 Shows Prolonged Tumor Retention With Limited Off-Target Radiation Exposure in Metastatic Castration-Resistant Prostate Cancer - Design/Population: The phase 3 PROSTACT Global trial evaluating TLX591 (lutetium-177 rosopatamab) plus investigator-selected standard of care versus…...
Convo-1" Produces Durable Responses in Patients Previously Treated With PSMA Radioligand Therapy
23+ hour, 54+ min ago (370+ words) Dr Morris presented these results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Hi, my name is Michael Morris. I'm the prostate cancer section head at Memorial Sloan Kettering Cancer Center. I'm presenting at ASCO…...
Novel Neoadjuvant Approach Expands Treatment Options for Patients With Melanoma
22+ hour, 27+ min ago (14+ words) HMP Global Learning Network...